Statins appear to lessen chance of developing breast cancer

According to a new study women who are taking the cholesterol-lowering drugs called statins, such as Lipitor or Mevacor, appear to have much less chance of developing breast cancer.

In a study of U.S. female veterans, Dr. Vikas Khurana from Louisiana State University Health Science Center in Shreveport and colleagues, compared statin use among 548 women with a history of breast cancer and almost 40,000 women without breast cancer. The average age of the women was 58 years and a total of 4,771 (12 percent), were using statins.

The researchers found that after taking into consideration age, tobacco and alcohol use, and diabetes the analysis showed that statin use was associated with a 51 percent reduced risk of breast cancer.

The study is further proof that statins have chemopreventive potential, and raises the question of whether everyone should be given statins, says Dr. Robert J Mayer from Dana Farber Cancer Institute in Boston who moderated the briefing.

Khurana says at present that is not appropriate but he says the study suggests a future trial could answer that question.

Currently, says Khurana there is some data that suggests that patients with lipid abnormalities and at high risk for cancer might be preferably put on a statin as compared to other lipid-lower agents, for its presumed cancer prevention action.

Khurana reported at a press briefing on advances in cancer prevention at the meeting of the American Society of Clinical Oncology.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MRI-guided SBRT reduces side effects in prostate cancer treatment